XMU-MP-1, Inhibitor of STE20-like MST1/2 Kinases of the Hippo Signaling Pathway, Suppresses the Cell Cycle, Activates Apoptosis and Autophagy, and Induces Death of Hematopoietic Tumor Cells
Open Access
- 12 June 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 874
Abstract
Background/Objectives: Currently, there is limited knowledge on the molecular mechanisms of the “non-canonical” Hippo signaling pathway in hematopoietic tumor cells. We have shown that targeting the MST1/2 kinases, which are the key molecules in this signaling pathway, may be an effective approach to the treatment of hematologic tumors. Methods: The methods used in this study include cell growth assays, caspase assays, Western blot hybridizations, flow cytometry, and whole-transcriptome analyses. These methods allowed us to better understand the molecular pathways at play. Results: Our results showed that XMU-MP-1, an inhibitor of MST1/2 kinase, specifically reduces the viability of hematopoietic cancer cells but not breast cancer cells. It effectively inhibits the growth of the tumor B- and T-cell lines by blocking cell cycle progression, mainly during the G2/M phase, inducing apoptosis and autophagy. XMU-MP-1 treatment led to increased caspase 3/7 activity and increased levels of the cleaved PARP protein. Levels of the LC3-II protein were also shown to be increased, while the level of p62 decreased. These changes are associated with apoptosis and autophagy, respectively. RNA-seq analysis has demonstrated that XMU-MP-1 suppressed the expression of cell cycle regulators, such as E2F, and cell division cycle genes CDC6,7,20,25,45; cyclins A2,B1,B2, and cyclin-dependent kinases. At the same time, it increased the expression of genes involved in apoptosis, autophagy, and necroptosis. Conclusions: Combinations of growth assays, caspase assays, Western blotting, and RNA-seq have shown that the dramatic reduction in the number of hematopoietic tumor cells after treatment with XMU-MP-1 is due to both cytostatic and cytotoxic effects. The use of MST1/2 kinase inhibitors could be highly promising for complex therapy of hematological tumors.Keywords
All Related Versions
Funding Information
- Ministry of Science and Higher Education of the Russian Federation (075-15-2019-1660, 124031800074-4)
- Program of Fundamental Research in the Russian Federation for the 2021–2030 period (075-15-2019-1660, 124031800074-4)
This publication has 34 references indexed in Scilit:
- The two sides of Hippo pathway in cancerSeminars in Cancer Biology, 2022
- The Hippo Signaling Pathway in Development and DiseaseDevelopmental Cell, 2019
- YAP/TAZ at the Roots of CancerCancer Cell, 2016
- MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathwayNature Communications, 2015
- YAP and TAZ: a nexus for Hippo signaling and beyondTrends in Cell Biology, 2015
- Spatial Organization of Hippo Signaling at the Plasma Membrane Mediated by the Tumor Suppressor Merlin/NF2Cell, 2013
- The Sterile 20-like Kinase Tao-1 Controls Tissue Growth by Regulating the Salvador-Warts-Hippo PathwayDevelopmental Cell, 2011
- Tao-1 Phosphorylates Hippo/MST Kinases to Regulate the Hippo-Salvador-Warts Tumor Suppressor PathwayDevelopmental Cell, 2011
- The human tumour suppressor LATS1 is activated by human MOB1 at the membraneBiochemical and Biophysical Research Communications, 2006
- Induction of autophagy and inhibition of tumorigenesis by beclin 1Nature, 1999